Take Solutions Ltd
Founded in 2001 as a software services provider, TAKE is currently a technology driven, full service Clinical Research Organization. It helps biopharma companies throughout the drug development process, and beyond. Headquartered in Chennai, India, it has a global footprint spanning the Americas, Europe and the Asia Pacific region.
The co. delivers domain-intensive services in Life Sciences.
TAKE is the only full-service technology-driven Clinical Research Organization listed in India.
It has 1,70,000 regulatory submissions and submitted 5% of all regulatory submissions to USFDA 2012 to 2020.[1] [1] [2] [3]
- Market Cap ₹ 323 Cr.
- Current Price ₹ 21.8
- High / Low ₹ 69.6 / 20.6
- Stock P/E
- Book Value ₹ 12.2
- Dividend Yield 0.00 %
- ROCE -79.5 %
- ROE -120 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Debtor days have improved from 121.86 to 45.40 days.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -13.39% over past five years.
- Company has a low return on equity of -28.90% for last 3 years.
- Contingent liabilities of Rs.848.84 Cr.
- Company's cost of borrowing seems high
- Promoter holding has decreased over last 3 years: -13.48%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: IT - Software Industry: Computers - Software - Medium / Small
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
500 | 704 | 832 | 816 | 730 | 1,030 | 1,345 | 1,587 | 2,039 | 2,213 | 774 | 655 | |
397 | 559 | 670 | 668 | 581 | 817 | 1,082 | 1,281 | 1,655 | 2,044 | 847 | 1,341 | |
Operating Profit | 103 | 145 | 161 | 147 | 149 | 213 | 262 | 307 | 384 | 169 | -73 | -686 |
OPM % | 21% | 21% | 19% | 18% | 20% | 21% | 20% | 19% | 19% | 8% | -9% | -105% |
6 | 15 | 7 | 6 | 8 | 21 | 13 | 6 | 11 | 26 | -211 | 17 | |
Interest | 8 | 18 | 14 | 14 | 13 | 15 | 23 | 21 | 25 | 41 | 37 | 29 |
Depreciation | 22 | 27 | 46 | 77 | 60 | 74 | 87 | 104 | 154 | 167 | 115 | 80 |
Profit before tax | 80 | 115 | 107 | 63 | 85 | 145 | 165 | 188 | 216 | -13 | -437 | -779 |
Tax % | 8% | 18% | 17% | 2% | 6% | 14% | 11% | 15% | 17% | 15% | -3% | -0% |
Net Profit | 70 | 86 | 79 | 58 | 70 | 120 | 143 | 160 | 177 | -12 | -452 | -782 |
EPS in Rs | 5.72 | 6.99 | 6.49 | 4.74 | 5.71 | 9.78 | 10.74 | 10.85 | 11.99 | -0.84 | -30.56 | -52.88 |
Dividend Payout % | 17% | 14% | 15% | 21% | 17% | 10% | 9% | 15% | 8% | -0% | -0% | -0% |
Compounded Sales Growth | |
---|---|
10 Years: | -1% |
5 Years: | -13% |
3 Years: | -32% |
TTM: | -15% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -236% |
Stock Price CAGR | |
---|---|
10 Years: | -5% |
5 Years: | -34% |
3 Years: | -44% |
1 Year: | -67% |
Return on Equity | |
---|---|
10 Years: | -3% |
5 Years: | -11% |
3 Years: | -29% |
Last Year: | -120% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
12 | 12 | 12 | 12 | 12 | 12 | 13 | 15 | 15 | 15 | 15 | 15 | |
Reserves | 243 | 330 | 408 | 458 | 512 | 619 | 898 | 1,314 | 1,504 | 1,561 | 1,110 | 166 |
185 | 193 | 196 | 207 | 209 | 336 | 237 | 323 | 474 | 553 | 514 | 65 | |
147 | 206 | 220 | 185 | 189 | 246 | 221 | 189 | 339 | 336 | 187 | 977 | |
Total Liabilities | 588 | 741 | 837 | 862 | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,465 | 1,826 | 1,223 |
267 | 339 | 368 | 384 | 359 | 543 | 554 | 589 | 1,091 | 1,234 | 934 | 101 | |
CWIP | 4 | 1 | 3 | 2 | 17 | 3 | 21 | 42 | 41 | 1 | 0 | 3 |
Investments | 50 | 50 | 50 | 50 | 6 | 21 | 10 | 59 | 10 | 18 | 7 | -0 |
266 | 351 | 415 | 426 | 541 | 647 | 785 | 1,150 | 1,188 | 1,213 | 885 | 1,119 | |
Total Assets | 588 | 741 | 837 | 862 | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,465 | 1,826 | 1,223 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
59 | 115 | 117 | 100 | 74 | 151 | 56 | 121 | 104 | 211 | 135 | ||
-201 | -81 | -70 | -91 | -14 | -292 | -130 | -179 | -474 | -233 | -57 | ||
141 | -21 | -31 | -7 | -11 | 111 | 56 | 302 | 100 | 21 | -84 | ||
Net Cash Flow | -1 | 13 | 16 | 2 | 49 | -30 | -18 | 243 | -270 | -2 | -6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 76 | 82 | 99 | 100 | 120 | 107 | 118 | 108 | 94 | 116 | 205 | 45 |
Inventory Days | ||||||||||||
Days Payable | ||||||||||||
Cash Conversion Cycle | 76 | 82 | 99 | 100 | 120 | 107 | 118 | 108 | 94 | 116 | 205 | 45 |
Working Capital Days | 68 | 55 | 71 | 83 | 121 | 107 | 136 | 143 | 142 | 137 | 289 | 49 |
ROCE % | 21% | 26% | 21% | 12% | 14% | 17% | 17% | 15% | 13% | 1% | -9% | -80% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Resignation of Director
9h - The Board of the Company, in its meeting held on Thursday, June 30, 2022, approved/took on record following: 1. Resignation of Mr. Venkataraman Murali from …
-
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)
9h - Mr. Lalit Kanta Mahapatra has resigned from the position of Chief Financial Officer of the Company w.e.f June 30, 2022. Please take note of the …
-
Announcement under Regulation 30 (LODR)-Change in Directorate
9h - The Board of the Company, in its meeting held on Thursday, June 30, 2022, approved/took on record following: 1. Appointment of Mr. Ramesh Gopal (DIN: …
- Closure of Trading Window 1d
-
Announcement under Regulation 30 (LODR)-Resignation of Director
1d - The Board of the Company, in its meeting held on Thursday, June 30, 2022, approved/took on record following: 1. Resignation of Mr. Narayanan Kumar from …
Annual reports
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Dec 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Mar 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Nov 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Dec 2016TranscriptPPT
-
Oct 2016TranscriptPPT
-
Feb 2016TranscriptPPT
Services
Life Sciences (94% of revenue in FY20): TAKE assists drug companies in bringing their products to the market and helps them sustain the drugs throughout their market life cycle.
Clinical Trials: It assists drug companies in conducting clinical trials of new drugs, aimed at evaluating their safety and efficacy.
Regulatory Affairs: it assists in the documentation and submission process of data and insights gathered at each stage of the drug development process to the regulatory bodies at predefined intervals.
Supply Chain Management (6% of revenue in FY 20): The Company's Supply Chain business in India is a JV with APA Engineering. [1] [2] [3]